Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Issa F. Khouri, Alison M. Gulbis, Denái R. Milton, Martin Korbling, MD, Celina Ledesma, Sairah Ahmed, Amin M. Alousi, MD, Betul Oran, MDMS, Paolo Anderlini, Stefan O. Ciurea, Roland L. Bassett, Jr., Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 3240.

https://doi.org/10.1182/blood.V130.Suppl_1.3240.3240

Published: 2017

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Issa F. Khouri, Elias J. Jabbour, MD, Celina Ledesma, Martin Korbling, MD, Amin M. Alousi, Paolo Anderlini, Betul Oran, MDMS, Stefan O. Ciurea, Luis E. Fayad, Roland L. Bassett, Jr., Alison M. Gulbis

Blood (2017) 130 (Supplement 1): 2036.

https://doi.org/10.1182/blood.V130.Suppl_1.2036.2036

Published: 2017

Journal Articles

Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, Hui Gao, Denái R. Milton, Martin Korbling, MD, Celina Ledesma, Luis E. Fayad, Elias J. Jabbour, MD, Alison M. Gulbis, James M. Reuben

Blood (2017) 130 (Supplement 1): 1925.

https://doi.org/10.1182/blood.V130.Suppl_1.1925.1925

Published: 2017

Journal Articles

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, MD, Francesco Turturro, MD, Denái R. Milton, Martin Korbling, MD, Barry I Samuels, BA, MD, Elias J. Jabbour, MD, Celina Ledesma, BS, Rosamar B Valverde, Hui Gao, PhD, Michelle A Fanale, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, James M Reuben, BS, MBA, MS, PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 5814.

https://doi.org/10.1182/blood.V128.22.5814.5814

Published: 2016

Journal Articles

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Blood (2015) 126 (23): 3192.

https://doi.org/10.1182/blood.V126.23.3192.3192

Published: 2015

Journal Articles

Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation

Blood (2015) 126 (23): 152.

https://doi.org/10.1182/blood.V126.23.152.152

Published: 2015

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Issa F. Khouri, MD, Rima M Saliba, PhD, Zijun Y. Xu-Monette, PhD, Martin Korbling, MD, Gabriela Rondon, MD, Rosamar Valverde, Amin M. Alousi, MD, Paolo Anderlini, MD, Sairah Ahmed, MD, Stefan O Ciurea, MD, Luis Fayad, MD, Betul Oran, MD, Simrit Parmar, Uday R. Popat, MD, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Alison M Gulbis, PharmD, BCOP, Ken H. Young, MD PhD

Blood (2014) 124 (21): 2563.

https://doi.org/10.1182/blood.V124.21.2563.2563

Published: 2014

Journal Articles

Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation

Fabian M Bock, Gary Lu, MD, Nina Shah, Qaiser Bashir, Krina K. Patel, MD, Uday R. Popat, MD, Chitra M. Hosing, Sameh Gaballa, MD, Martin Korbling, MD, Ruby Delgado, Gabriela Rondon, MD, Robert Z. Orlowski, MD, PhD, Jatin J. Shah, Elisabet E. Manasanch, MD, Richard E. Champlin, Muzaffar H. Qazilbash, MD

Blood (2014) 124 (21): 2521.

https://doi.org/10.1182/blood.V124.21.2521.2521

Published: 2014

Journal Articles

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

Issa F. Khouri, Wei Wei, Martin Korbling, Francesco Turturro, Sairah Ahmed, Amin Alousi, Paolo Anderlini, Stefan Ciurea, Elias Jabbour, Betul Oran, Uday R. Popat, Gabriela Rondon, Roland L. Bassett, Jr, Alison Gulbis

Blood (2014) 124 (14): 2306–2312.

https://doi.org/10.1182/blood-2014-07-587519

Published: 2014

Journal Articles

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Issa F. Khouri, MD, Hui Gao, PhD, Wei Wei, MS, Martin Korbling, MD, Celina Ledesma, BS, Rosamar Valverde, MD, Alison M Gulbis, PharmD, BCOP, James M Reuben, PhD

Blood (2013) 122 (21): 4518.

https://doi.org/10.1182/blood.V122.21.4518.4518

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Issa F. Khouri, MD, Wei Wei, MS, Rosamar Valverde, MD, Martin Korbling, MD, Francesco Turturro, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Amin Alousi, MD, Betul Oran, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Roland Bassett

Blood (2013) 122 (21): 541.

https://doi.org/10.1182/blood.V122.21.541.541

Published: 2013

Journal Articles

Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation

Issa F. Khouri, MD, Saliba M. Rima, MD, Francesco Turturro, MD, Martin Korbling, MD, Celina Ledesma, Gabriela Rondon, MD, Amin M. Alousi, M.D., Paolo Anderlini, MD, Qaiser Bashir, MD, Stefan O. Ciurea, Chitra M. Hosing, M.D., Uday R. Popat, M.D., Yasmeen Charafeddine, Yasuhiro Oki, MD, Luis E Fayad, MD, Richard E. Champlin

Blood (2012) 120 (21): 4157.

https://doi.org/10.1182/blood.V120.21.4157.4157

Published: 2012

Journal Articles

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Blood (2012) 119 (26): 6373–6378.

https://doi.org/10.1182/blood-2012-03-417808

Published: 2012

Journal Articles

Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation

Stefan O. Ciurea, Peter F. Thall, Xuemei Wang, Sa A. Wang, Ying Hu, Pedro Cano, Fleur Aung, Gabriela Rondon, Jeffrey J. Molldrem, Martin Korbling, Elizabeth J. Shpall, Marcos de Lima, Richard E. Champlin, Marcelo Fernandez-Vina

Blood (2011) 118 (22): 5957–5964.

https://doi.org/10.1182/blood-2011-06-362111

Published: 2011

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Journal Articles

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Issa F Khouri, MD, Rima M Saliba, PhD, Martin Korbling, MD, Amin M Alousi, MD, Uday R Popat, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Partow Kebriaei, MD, Muzaffar H. Qazilbash, MD, Richard Champlin, MD, Roland L Bassett, Jr.

Blood (2011) 118 (21): 894.

https://doi.org/10.1182/blood.V118.21.894.894

Published: 2011

Journal Articles

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,

Amer Beitinjaneh, MD, MPH, Rima M. Saliba, PhD, Grace-Julia Okoroji, Martin Korbling, MD, Amin M Alousi, MD, Uday Popat, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Borje S Andersson, MD, PhD, Partow Kebriaei, MD, Chitra M Hosing, MD, Muzaffar Qazilbash, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Richard Champlin, MD, Issa Khouri, MD

Blood (2011) 118 (21): 4118.

https://doi.org/10.1182/blood.V118.21.4118.4118

Published: 2011

NARROW

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only